INS and COVID-19: For example, some of the anti-diabetic drugs such as biguanides, SGLT2 inhibitors, DPP-4 inhibitors, sulfonylureas, and insulin, which have been commonly administered for the management of type-2 diabetes, are reported to exacerbate the clinical conditions in COVID-19.